相关实验视频
Updated: Mar 4, 2026

Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
氨基阿达曼坦如何阻断流感M2通道,抗药性如何发展?
Hadas Leonov1, Peleg Astrahan, Miriam Krugliak
1Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Edmund J. Safra Campus, Jerusalem 91904, Israel.
氨基亚达曼类通过静电阻碍阻断流感M2通道. 突变通过扩大结合口袋引起耐药性,允许药物流动性和防止阻塞,帮助新的抗病毒设计.
科学领域:
- 生物物理学的生物物理.
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 离子通道阻断剂在生物医学和药物开发中至关重要.
- 流感M2通道阻断剂,阿曼塔丁和里曼塔丁,是重要的抗流感药物.
- 了解耐药性机制是开发有效抗病毒药物的关键.
研究的目的:
- 为了阐明由氨基-阿达曼提尔阻塞流感M2通道的阻塞机制.
- 为了研究M2通道药物耐药性的分子基础.
- 为下一代流感治疗药物的设计提供信息.
主要方法:
- 对通道阻塞相互作用的计算分析.
- 计算发现的实验验证.
- 分析M2通道突变及其对耐药性的影响.
主要成果:
- 氨基亚达曼提尔通过其带电氨基基组的静电阻碍来抑制M2 H(+) 通道活性.
- 单独的阿达曼基组不会影响通道导电性.
- 突变在M2中产生更大的结合口袋,允许药物结合,但保持通道功能并赋予耐药性.
- 药物在突变通道中的流动性可以防止静电阻碍.
结论:
- 氨基亚达曼提尔的正电荷氨基群对于M2通道阻塞至关重要.
- 耐药性源于突变,这些突变增加了结合口袋的大小,降低了药物的疗效.
- 获得的见解可以指导新型抗流感药物的开发,这些药物可以有效地对抗抗性菌株.
更多相关视频
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
09:39Co-immunoprecipitation of the Mouse Mx1 Protein with the Influenza A Virus Nucleoprotein
Published on: April 21, 2015
相关概念视频
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...